BR112012029396A2 - métodos relativos a um micoplasma atenuado. - Google Patents

métodos relativos a um micoplasma atenuado.

Info

Publication number
BR112012029396A2
BR112012029396A2 BR112012029396A BR112012029396A BR112012029396A2 BR 112012029396 A2 BR112012029396 A2 BR 112012029396A2 BR 112012029396 A BR112012029396 A BR 112012029396A BR 112012029396 A BR112012029396 A BR 112012029396A BR 112012029396 A2 BR112012029396 A2 BR 112012029396A2
Authority
BR
Brazil
Prior art keywords
bacterium
mycoplasma
methods related
attenuated mycoplasma
attenuated
Prior art date
Application number
BR112012029396A
Other languages
English (en)
Inventor
Youil Rima
Abs El-Osta Youssef
Original Assignee
Bioproperties Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010902198A external-priority patent/AU2010902198A0/en
Application filed by Bioproperties Pty Ltd filed Critical Bioproperties Pty Ltd
Publication of BR112012029396A2 publication Critical patent/BR112012029396A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos relativos a um micoplasma atenuado - a presente invenção refere-se a um método para identificar ou gerar uma bactéria de mycoplasma atenuado em que a bactéria compreende uma mutação em pelo menos um gene como listado e uso da bactéria em uma vacina para suscitar imunidade protetora contra mycoplasma ou para detectar infecção através da dita bactéria.
BR112012029396A 2010-05-19 2011-05-19 métodos relativos a um micoplasma atenuado. BR112012029396A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010902198A AU2010902198A0 (en) 2010-05-19 Methods relating to an attenuated mycoplasma
PCT/AU2011/000584 WO2011143706A1 (en) 2010-05-19 2011-05-19 Methods relating to an attenuated mycoplasma

Publications (1)

Publication Number Publication Date
BR112012029396A2 true BR112012029396A2 (pt) 2019-09-24

Family

ID=44991084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029396A BR112012029396A2 (pt) 2010-05-19 2011-05-19 métodos relativos a um micoplasma atenuado.

Country Status (11)

Country Link
US (1) US9260691B2 (pt)
EP (1) EP2571980A4 (pt)
JP (1) JP2013526866A (pt)
KR (1) KR20130086154A (pt)
CN (1) CN102985530A (pt)
AU (1) AU2011256137B2 (pt)
BR (1) BR112012029396A2 (pt)
CA (1) CA2799732A1 (pt)
EA (1) EA201291175A1 (pt)
MX (1) MX2012013409A (pt)
WO (1) WO2011143706A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684959A1 (en) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
CN114940955B (zh) * 2022-05-10 2023-08-11 兆丰华生物科技(南京)有限公司 一种鸡毒支原体弱毒疫苗株及其应用
CN117690485B (zh) * 2024-02-04 2024-05-28 北京诺禾致源科技股份有限公司 用于寄生虫鉴定的基因组的处理方法和处理装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914160A (pt) 1998-09-30 2001-06-26 American Cyanamid Co Composição antigênica, método para aumentar a capacidade de uma composição antigênica que contenha um antìgeno selecionado de uma bactéria, vìrus, fungo ou parasita patogênicos, do haemophilus influenzae, do helicobacter pylori, do vìrus sincicial respiratório, do rotavìrus, e, do vìrus simples do herpes para evocar a resposta imune de um hospedeiro vertebrado, plasmìdeo, célula hospedeira, método para produzir uma holotoxina do cólera mutante imunogênica, e, uso de uma quantidade auxiliar eficaz de uma holotoxina do cólera mutante
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
BRPI0710550A2 (pt) * 2006-04-10 2011-08-16 Intervet Int Bv uso de uma dose imunogênica de material imunogênico de mycoplasma hyopneumoniae e uma dose imunogênica de vìrus de prrs atenuado vivo, kit de vacina, e, método para a vacinação de porcos
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
CL2008002675A1 (es) * 2007-09-11 2008-11-07 Wyeth Corp Bacteria de mycoplasma gallisepticum atenuada; composicion de vacuna que la comprende; método de vacunación; y método de identificación de clones de mycoplasma gallisepticum atenuados.
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
MX2011007606A (es) * 2009-02-20 2011-08-08 Australian Poultry Crc Pty Ltd Vacunas atenuadas vivas.
EP2453913B1 (en) * 2009-05-19 2016-06-22 Bioproperties Pty Ltd A temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof

Also Published As

Publication number Publication date
AU2011256137A1 (en) 2012-11-29
CA2799732A1 (en) 2011-11-24
JP2013526866A (ja) 2013-06-27
EP2571980A1 (en) 2013-03-27
EP2571980A4 (en) 2014-02-26
MX2012013409A (es) 2013-03-07
AU2011256137B2 (en) 2015-01-22
US9260691B2 (en) 2016-02-16
WO2011143706A1 (en) 2011-11-24
KR20130086154A (ko) 2013-07-31
EA201291175A1 (ru) 2013-06-28
US20130243819A1 (en) 2013-09-19
CN102985530A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
BR112016003127A2 (pt) “composições e métodos para modular rna”
BR112012004698A2 (pt) métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada.
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112013005329A2 (pt) variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
BRPI0815008B8 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
BR112012027747A2 (pt) método e composição imunogênica para tratamento de neoplásia
BR112014013876A2 (pt) vacina à base de toxina de clostridium difficile
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
BR112012020628A2 (pt) fotoiniciador de éter polialquílico, uso de um fotoiniciador de éter polialquílico, método para curar uma composição de matriz, e, composição de matriz
BR112014018732A8 (pt) Composições imunogênicas contra campylobacter e usos das mesmas
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
CL2008002675A1 (es) Bacteria de mycoplasma gallisepticum atenuada; composicion de vacuna que la comprende; método de vacunación; y método de identificación de clones de mycoplasma gallisepticum atenuados.
BR112015021210A2 (pt) métodos e composições para o direcionamento de rna polimerases e biogênese de rna não codificante para locais específicos
MX2010000864A (es) Vacuna de celulas enteras estafilococcicas inactivadas.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112012008150A2 (pt) sistema e método para verificar a idade de um usuário de internet
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
BR112017000022A2 (pt) nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.